PolyActiva awarded $1.5m CUREator Grant
PolyActiva has recently been awarded a $1.5m CUREator Grant, which will be used to progress its second generation ocular implant as a treatment for patients with glaucoma, targeting sustained daily…
PolyActiva has recently been awarded a $1.5m CUREator Grant, which will be used to progress its second generation ocular implant as a treatment for patients with glaucoma, targeting sustained daily…
PolyActiva reports promising clinical trial results for its 6-month sustained drug delivery, biodegradable ocular implant in glaucoma patients. The interim Phase 2a results demonstrate a sustained >20% reduction of IOP…
PolyActiva presents positive clinical trial results at the 2022 American Glaucoma Society Annual Meeting - March 2022
PolyActiva announces positive Phase IIa results in glaucoma trial with low dose cohort.
PolyActiva successfully completes initial clinical trial with Latanoprost FA SR Ocular Implant delivering glaucoma treatment to patients over a six-month period.
PolyActiva successfully completes initial clinical trial with Latanoprost FA SR Ocular Implant delivering glaucoma treatment to patients over a six-month period.
PolyActiva completes recruitment in key Phase I glaucoma implant safety study. Six-month treatment period demonstrated.
PolyActiva commences its first Phase I clinical trial.
PolyActiva raises AUD$9.2M in Series B venture funding.
© 2023 PolyActiva. All Rights Reserved. Caution: PolyActiva products are not for sale in the US